Decibel Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA



Growjo Ranking



Estimated Revenue & Valuation

  • Decibel Therapeutics's estimated annual revenue is currently $14.6M per year.(i)
  • Decibel Therapeutics received $55.0M in venture funding in June 2018.
  • Decibel Therapeutics's estimated revenue per employee is $173,452
  • Decibel Therapeutics's total funding is $189.2M.
  • Decibel Therapeutics's current valuation is $116.1M. (January 2022)

Employee Data

  • Decibel Therapeutics has 84 Employees.(i)
  • Decibel Therapeutics grew their employee count by 5% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing. Hearing loss is the most prevalent form of sensory impairment. It is estimated that 50 million people in the U.S., and 360 million people worldwide, suffer from some type of hearing loss. Hearing disorders affect people of all ages and can have a profound impact on quality of life. By combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, Decibel is pioneering a comprehensive approach to defining and treating the underlying biological causes of hearing disorders, and developing a pipeline of breakthrough drugs targeted to specific indications and patients. Founded by the world's preeminent experts in inner ear biology and hearing disorders, Decibel Therapeutics was launched in 2015 by Third Rock Ventures and SR One and is headquartered in Boston, Mass. For more information and to browse career opportunities at Decibel Therapeutics, please visit

keywords:Biotechnology,Healthcare,Medical Devices,Medical Diagnostics


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Decibel Therapeutics News

2022-04-17 - A promising cancer drug leads Regeneron to reconsider its ...

... believes will be a valuable component in cancer-fighting combination therapies. ... Intellia Therapeutics and Decibel Therapeutics.

2022-04-13 - Reviewing AstraZeneca (NASDAQ:AZN) & Decibel ...

Decibel Therapeutics is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the...

2022-04-13 - Decibel Therapeutics (NASDAQ:DBTX) Stock Rating ...

Decibel Therapeutics (NASDAQ:DBTX) Stock Rating Upgraded by Zacks Investment Research. Posted by admin on Apr 14th, 2022.

2020-11-10 - Decibel Therapeutics lands $82M+ for hearing loss treatment

Decibel Therapeutics, a developer of treatments for hearing loss and balance disorders, has raised $82.2 million in an oversubscribed Series D. The round was led by OrbiMed, with new investors such as BlackRock Health Sciences, Janus Henderson, Casdin Capital and Surveyor Capital also joining. D ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Decibel Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-10-16$52.0MAThird Rock Ventures LLCArticle

Decibel Therapeutics Executives

Laurence ReidCEO
Elisabeth LeidermanChief Financial Officer and Head of Corporate Development
Anna TraskChief People, Community and Culture Officer
Cynthia HuChief Legal Officer and Corporate Secretary
John KeiltyChief Data Sciences Officer
Michael SuChief Scientific Officer
Laurence ReidChief Executive Officer
Peter WeberCMO
Paula CobbChief Operating Officer
Elisabeth LeidermanChief Financial Officer & Head of Corporate Development
John LeeChief Development Officer
Patrick HylandEVP, Chief People Officer
Elaine CopeVice President, Operations
Sandra AbbottSenior Scientist, VP/PD AAV Gene Therapy
Adam PalermoVice President, Head of Genomics and Computational Biology
Joe BurnsVice President, Discovery
Elaine KernbauerVice President, Development Operations
Jonathon WhittonSenior Vice President Clinical Research and Development
Heather WolffVice President, Clinical Development Operations
Ada SilosVP Pharmacology
Bridget CleffVice President, New Product Planning
Patrick HylandEVP, Chief People Officer